DV
Dividend Vision

LKFT — Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV (LKFT)

Total return is 275.6% over the past 18.1 years, 487.6 points behind SPY at 763.2%. Its deepest 1-year drawdown was 30.7%.

Lakefront Biotherapeutics NV is a biotechnology company developing medicines in oncology and immunology, with a pipeline that includes GLPG3667 for autoimmune conditions in phase 2 trials, and CAR-T cell therapies (GLPG5101 and GLPG5301) in phase 1/2 development for blood cancers and multiple myeloma; the company also maintains a collaboration with Gilead Sciences. The company does not currently distribute dividends. Lakefront Biotherapeutics appeals to investors seeking exposure to early-stage biopharmaceutical development with a focus on cell therapy innovation, rather than to income-focused investors.

LKFT key facts

Asset type
Stock
Asset class
Equity
Inception date
07/07/2008
Last close
$27.53
Market cap
$1,900,365,184
Average volume
249300.0
Beta
0.12
Payout ratio
0.0
P/E ratio
3.4384
Forward P/E
344.8276
EPS
$8.44